Welcome to our dedicated page for Movano news (Ticker: MOVE), a resource for investors and traders seeking the latest updates and insights on Movano stock.
Movano Inc. (Nasdaq: MOVE), doing business as Movano Health, generates news at the intersection of wearable medical devices, health technology, and corporate transformation. Founded in 2018, the company develops devices such as the Evie and EvieMED rings, which are designed to bring medical-grade data into consumer and enterprise wearables. Its disclosures highlight capabilities that span physiological monitoring, women’s wellness, and proprietary RF-based sensing for cuffless blood pressure and noninvasive glucose monitoring.
News coverage of Movano frequently includes product and technology updates. The company has announced clinical study results for its wrist-worn cuffless blood pressure prototype, noting accuracy within standards recognized by the FDA for wearable, cuffless blood pressure devices and the ability to collect additional vital signs such as pulse rate, SpO2, respiration rate and ECG waveforms. It has also reported enhancements to the Evie Ring’s companion app, including new personalization and trend-tracking features, integration with Apple Health, expanded workout logging, and the introduction of EvieAI, a virtual wellness assistant built from medical journal data.
Movano’s news flow also reflects regulatory and listing developments. The company has issued multiple press releases regarding Nasdaq notifications related to bid price, periodic filing timeliness, and stockholders’ equity requirements, as well as its responses, such as engaging a new independent auditor, submitting compliance plans, and implementing a one-for-ten reverse stock split to support bid price compliance. Investors following MOVE news can track how these steps affect the company’s continued listing on the Nasdaq Capital Market.
A significant portion of recent headlines centers on strategic and transactional events. Movano’s board initiated a process to explore strategic alternatives, including a sale or merger, to maximize shareholder value. This process led to a definitive Agreement and Plan of Merger with Corvex, Inc., an AI cloud computing company specializing in GPU-accelerated infrastructure. Related announcements describe the planned all-stock combination, ownership structure expectations, concurrent financings, and the intention to rename Movano Inc. as Corvex, Inc. upon closing, with the combined company headquartered in Arlington, Virginia. Movano has also communicated that it may market for sale its current operating assets, including the EvieMED Ring and its mmWave RF technology, prior to completion of the merger.
By monitoring the MOVE news feed, readers can follow updates on Movano’s wearable health products, clinical and regulatory milestones, listing status, financing activities, and the progress of its proposed merger with Corvex. This stream of information helps investors and observers understand both the company’s health technology initiatives and its potential evolution into a public vehicle for AI infrastructure through the planned combination.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Movano Inc. (NASDAQ: MOVE), operating as Movano Health, will report its first quarter 2023 financial and operating results on May 15, 2023. Management will host a conference call at 9:00 a.m. PDT (12:00 p.m. EDT) to discuss these results and provide a business update.
The company focuses on developing healthcare solutions that merge medical-grade data with consumer health devices to empower users in managing their health. Their product, the Evie Ring, aimed specifically at women's health, is set to launch in summer 2023. Interested parties can access the live webcast or conference call through the company’s investor relations website.
Movano Health (Nasdaq: MOVE) reported its Q4 and full-year 2022 financial results, revealing a net loss of $7.9 million for Q4, compared to $6.3 million in Q4 2021. For the year, the net loss was $30.3 million, consistent with the previous year. The company is preparing for the summer 2023 launch of its first product, the Evie Ring, and is conducting beta tests with multiple partners. Movano Health has filed for FDA clearance and has received nine new U.S. patents for its non-invasive monitoring technologies. The company ended 2022 with $10.8 million in cash. Additionally, it raised $7.5 million in a recent public offering to support product development.
Movano Health (NASDAQ: MOVE) has secured three new patents for its radio frequency (RF) technology aimed at enhancing health monitoring capabilities. The newly issued patents increase Movano's intellectual property portfolio to 21 patents issued and 38 pending. Notably, these patents focus on monitoring critical health metrics such as blood glucose levels, blood pressure, and heart rate. The proprietary System-on-a-Chip (SoC) allows for improved accuracy and compact device design. The SoC is set for clinical testing in March 2023, with future integration planned for Movano's wearables.